Brisbane, CA, November 9, 2020 – FlemingMartin is pleased to announce that Myovant Sciences (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on redefining care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, has hired Carmen Merritt as an Executive Director and Human Resources Business Partner.
Carmen brings many years of strategic HR leadership to Myovant from her tenures with well-known biotechnology companies such as MyoKardia, Five Prime Therapeutics, Onyx Pharmaceuticals, Novartis, Amgen, and Ocular Sciences. Carmen possesses deep expertise serving as an HRBP to executive leaders across numerous functions, she is also very passionate about leading organizational development and coaching initiatives. Carmen holds a B.A. in Economics from the University of California, Berkeley.
Myovant Sciences (NYSE: MYOV) is a clinical stage biopharmaceutical company focused on redefining care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant’s experienced team brings significant breadth and depth of expertise in drug development, combined with a commitment to develop new treatments for women suffering from uterine fibroids, endometriosis, and infertility, and for men suffering from prostate cancer. myovant.com
FlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards and CEOs to build successful, execution-focused management teams. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital. Learn more at flemingmartin.com